ArticleslgStudy

chemistry

Tasquinimod

Tasquinimod is a chemistry topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Tasquinimod rather than just read about it. In short: Tasquinimod (ABR-215050, CID 54682876) is an experimental drug currently being investigated for the treatment of solid tumors. Tasquinimod has been mostly studied in prostate cancer, but its mechanism of action suggests that it could be used to treat other cancers.

Tasquinimod — main illustration
Tasquinimod — illustration

Key takeaways

  • Tasquinimod belongs to chemistry; place it in that map before memorising details.
  • Learn the definition first, then one example that makes the definition concrete.
  • Connect Tasquinimod to a quantity you can measure, compute or draw — that is where exam questions come from.
  • Reproduce the core statement of Tasquinimod from memory before moving on to harder problems.

Reference excerpt

Tasquinimod (ABR-215050, CID 54682876) is an experimental drug currently being investigated for the treatment of solid tumors. Tasquinimod has been mostly studied in prostate cancer, but its mechanism of action suggests that it could be used to treat other cancers. Castration-resistant prostate cancer (CRPC), formerly called hormone-resistant or hormone-refractory prostate cancer, is prostate cancer that grows despite medical or surgical androgen deprivation therapy. Tasquinimod targets the tumor microenvironment and counteracts cancer development by inhibiting angiogenesis and metastasis and by modulating the immune system. It is now in phase III development, following successful phase II trial outcomes.

History Collaborative studies by laboratories at Johns Hopkins School of Medicine and Active Biotech Research AB identified tasquinimod as the lead agent for developing a treatment for prostate cancer. Tasquinimod was one of several second-generation quinoline-3-carboxamide variants synthesized using the drug roquinimex as a starting point, and it performed well in pre-clinical studies of cancer models. In April 2011, Ipsen and Active Biotech entered into a broad partnership for the co-development of tasquinimod for the treatment of cancer. Active Biotech granted Ipsen exclusive rights to commercialize tasquinimod worldwide, except in North and South America and Japan where Active Biotech retained all commercial and marketing rights.

Mechanism of action Tasquinimod is a novel small-molecule inhibitor that targets the tumor microenvironment by controlling the accumulation and immunosuppressive, pro-angiogenic and pro-metastatic functions of regulatory myeloid cells (also called myeloid-derived suppressor cells). It binds to and inhibits the interactions of S100A9, an immunomodulatory protein that promotes tumor development, influences suppressive and pro-angiogenic cells in the tumor microenvironment, and participates in the establishment of pre-metastatic niches. Tasquinimod may also target the tumor microenvironment by suppressing the tumor hypoxic response, in which genes involved in the adaptation and survival of cells during hypoxia are induced. Tasquinimod reduces tumor angiogenesis; but its anti-angiogenic effects do not appear to be linked to vascular endothelial growth factor (VEGF) neutralization or VEGF receptor tyrosine kinase inhibition.

Clinical studies A randomized, double-blind, placebo-controlled phase II study comparing tasquinimod with placebo in 206 men with metastatic CRPC was completed in 2009. The primary endpoint in the trial was to show a difference in the number of patients with disease progression at 6 months. The proportion of patients who were disease progression-free after 6 months was 69% for patients treated with tasquinimod versus 37% for placebo-treated patients (p<0.001). Median progression-free survival (PFS) was significantly improved in patients treated with tasquinimod compared with patients receiving placebo (7.6 vs 3.3 months; hazard ratio [HR] 0.57; 95% confidence interval [CI] 0.39, 0.85, p=0.0042). Tasquinimod thus delayed disease progression by about 4.3 months. Overall survival (OS) observed for tasquinimod-treated patients was longer than previously reported in this patient population. Median overall survival was 33.4 months for the tasquinimod group versus 30.4 months for the placebo group (p=0.49). Using a multivariate analysis, treatment with tasquinimod was associated with an OS advantage with a HR of 0.64 (95% CI 0.42, 0.97, p=0.034). It was hypothesized that the prolongation in PFS observed with tasquinimod treatment may lead to a survival advantage in men with metastatic CRPC. Also, a stronger trend for survival benefit was seen in patients with bone metastases; 34.2 for the tasquinimod group vs 27.1 months for the placebo group (HR 0.73, 95% CI 0.46, 1.17, p=0.19). Analysis of up to 3 years of safety data from phase II studies showed that treatment-related adverse events were mild to moderate, manageable and less frequent after 2 months of therapy. Adverse events observed included gastrointestinal disorders, fatigue, musculoskeletal pain as well as elevations of some laboratory parameters. A phase III randomized controlled trial called 10TASQ10 to confirm tasquinimod's effect on disease progression is ongoing. More than 1,200 patients with asymptomatic to mildly symptomatic metastatic CRPC were successfully enrolled in the study, as planned in the clinical protocol. The study is expected to complete in 2016. Other indications are currently under investigation.

References

Illustrations

Tasquinimod illustration

Worked examples

Example 1 — a first encounter with Tasquinimod

Start with the simplest possible case. Write down what Tasquinimod claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In chemistry, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Tasquinimod before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Tasquinimod ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Tasquinimod

In research
Tasquinimod appears in chemistry research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry
Engineering practice reuses Tasquinimod in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom
Tasquinimod is common in secondary-school and first-year university syllabi. It links to neighbouring topics 2-Quinolone ethers, 4-(Trifluoromethyl)phenyl compounds, Anilides, so understanding it makes those chapters shorter.
In everyday life
Look for Tasquinimod outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.
Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Tasquinimod” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Tasquinimod in 20 minutes

  1. Read the reference excerpt below once, without taking notes.
  2. Close the page and write down what Tasquinimod means in your own words.
  3. Compare your version with the excerpt and mark what you missed.
  4. Work through the three examples above with pen and paper.
  5. Explain Tasquinimod out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Tasquinimod in simple terms?

Tasquinimod (ABR-215050, CID 54682876) is an experimental drug currently being investigated for the treatment of solid tumors. Tasquinimod has been mostly studied in prostate cancer, but its mechanism of action suggests that it could be used to treat other cancers.

Why does Tasquinimod matter?

Because it connects several chemistry ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Tasquinimod?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Tasquinimod.

Tags

  • 2-Quinolone ethers
  • 4-(Trifluoromethyl)phenyl compounds
  • Anilides
  • Experimental cancer drugs
  • Quinolinols

Keep exploring